| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
HSV 0.3 μg/mL (IC50)
Ganoderone A targets herpes simplex virus (HSV), exhibiting antiviral activity with an IC₅₀ of 0.3 µg/mL. It is a tetracyclic triterpenoid that is 5alpha-lanosta-8,24-diene substituted by a hydroxy group at position 26 and oxo groups at positions 3 and 7. Ganoderone A also shows cytotoxic activity against cancer cell lines. It functions as a metabolite and an anti-HSV-1 agent. The compound's targets include viral replication mechanisms and cancer cell survival pathways. |
|---|---|
| ln Vitro |
Ganoderone A shows cytotoxic action with IC50 values of 7.62 µM, 6.28 µM, and 3.55 µM against K562, BEL7402, and SGC790 cell lines, respectively [3].
In vitro, Ganoderone A demonstrates potent antiviral activity against HSV with an IC₅₀ of 0.3 µg/mL. It exhibits cytotoxic activity against various cancer cell lines with IC₅₀ values of 7.62 µM against K562 leukemia cells, 6.28 µM against BEL7402 liver cancer cells, and 3.55 µM against SGC790 gastric cancer cells. These activities support its potential as an antiviral and anticancer agent. The compound's triterpenoid structure contributes to its biological activities. |
| ln Vivo |
In vivo data for Ganoderone A is limited in publicly available sources. As a triterpenoid compound with antiviral activity against HSV in vitro, Ganoderone A has potential applications in animal models of herpes simplex virus infection. The compound's cytotoxic activity against cancer cell lines suggests potential antitumor efficacy in vivo. However, specific published in vivo efficacy studies are not widely reported. Ganoderone A is primarily used as a research compound for studying antiviral and anticancer mechanisms.
|
| Enzyme Assay |
The in vitro antiviral assay for Ganoderone A involves testing the compound against herpes simplex virus in cell culture. Virus-infected cells are treated with varying concentrations of Ganoderone A, and viral replication is measured by plaque reduction assay or by quantifying viral DNA using PCR. IC₅₀ values are calculated from dose-response curves. Cytotoxicity assays against cancer cell lines such as K562, BEL7402, and SGC790 are performed using standard cell viability assays such as MTT or CellTiter-Glo. IC₅₀ values are determined after 48-72 hours of treatment.
|
| Cell Assay |
Cellular assays for Ganoderone A are conducted in HSV-infected cell lines and cancer cell lines including K562 (leukemia), BEL7402 (liver cancer), and SGC790 (gastric cancer). Cells are treated with varying concentrations of Ganoderone A for 48-72 hours. Cell viability is measured using standard assays such as MTT or CellTiter-Glo. Antiviral activity is assessed by measuring viral replication in infected cells. The compound's effects on cell cycle and apoptosis may be evaluated by flow cytometry.
|
| Animal Protocol |
In vivo studies for Ganoderone A would typically involve animal models of HSV infection or xenograft mouse models of cancer. The compound would be administered via intraperitoneal or oral routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring viral loads in tissues for antiviral studies or tumor growth inhibition for anticancer studies. However, specific published in vivo protocols for Ganoderone A are not available in the current literature. The compound is currently used as a research tool.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Ganoderone A is not extensively reported in publicly available sources. The compound has a molecular weight of 454.68 g/mol and a molecular formula of C₃₀H₄₆O₃. It has a density of 1.1±0.1 g/cm³, a boiling point of 568.0±50.0 °C, and a logP of 6.79. Suggested in vivo formulations include 5% DMSO + 30% PEG300 + 5% Tween 80. As a triterpenoid, it is expected to have moderate oral bioavailability. Detailed PK parameters are not available in the current literature.
|
| Toxicity/Toxicokinetics |
Toxicity data for Ganoderone A is limited in publicly available sources. As with all research compounds, Ganoderone A is intended for research use only and not for human therapeutic applications. The compound's natural origin from Ganoderma species suggests a potential safety profile, but comprehensive toxicology studies have not been reported. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
Ganoderone A is a tetracyclic triterpenoid compound with the structure 5α-lanostane-8,24-diene, substituted with a hydroxyl group at position 26 and carbonyl groups at positions 3 and 7. It was isolated from the fruiting body of Ganoderma pfeifferi and possesses anti-herpes simplex virus (HSV) activity. It is both a metabolite of HSV-1 and an active ingredient against HSV-1. Ganoderone A is a tetracyclic triterpenoid compound, and also a diketone and primary alcohol. It is derived from the hydride of lanostane. Ganoderone A has been reported in Ganoderma pfeifferi and Ganoderma leucocontextum.
Ganoderone A is a tetracyclic triterpenoid isolated from Ganoderma pfeifferi and Ganoderma calidophilum fruiting bodies. It exhibits antiviral activity against HSV with an IC₅₀ of 0.3 µg/mL. The compound also shows cytotoxic activity against cancer cell lines K562 (IC₅₀ = 7.62 µM), BEL7402 (IC₅₀ = 6.28 µM), and SGC790 (IC₅₀ = 3.55 µM). Ganoderone A is 5alpha-lanosta-8,24-diene substituted by a hydroxy group at position 26 and oxo groups at positions 3 and 7. It has potential applications in viral infections and tumors. Ganoderone A serves as a valuable research tool for studying antiviral and anticancer mechanisms. |
| Molecular Formula |
C30H46O3
|
|---|---|
| Exact Mass |
454.344
|
| CAS # |
873061-79-1
|
| PubChem CID |
11705156
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
568.0±50.0 °C at 760 mmHg
|
| Flash Point |
311.4±26.6 °C
|
| Vapour Pressure |
0.0±3.5 mmHg at 25°C
|
| Index of Refraction |
1.542
|
| LogP |
6.79
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
908
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@]12CC[C@H]([C@H](C)CC/C=C(\C)/CO)[C@@]1(C)CCC1[C@]3(CCC(=O)C(C)(C)[C@@H]3CC(C2=1)=O)C
|
| InChi Key |
SDAWCNCFVWQZDP-GOUGDUPLSA-N
|
| InChi Code |
InChI=1S/C30H46O3/c1-19(18-31)9-8-10-20(2)21-11-16-30(7)26-22(12-15-29(21,30)6)28(5)14-13-25(33)27(3,4)24(28)17-23(26)32/h9,20-21,24,31H,8,10-18H2,1-7H3/b19-9+/t20-,21-,24+,28-,29-,30+/m1/s1
|
| Chemical Name |
(5R,10S,13R,14R,17R)-17-[(E,2R)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-2,5,6,11,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-3,7-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
